Silexion Therapeutics Moves Forward with SIL204
Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the company’s plans for regulatory submissions.
Understanding SIL204's Mechanism
The SIL204 therapy is specifically engineered to disrupt the action of mutated KRAS proteins that contribute to aggressive forms of cancer, particularly pancreatic cancer. The preclinical data has already suggested that SIL204 can effectively inhibit cancer cell growth in various KRAS mutant cell lines. By focusing on the modifications made to enhance delivery and stability, Silexion aims for SIL204 to exhibit notable antitumor activity.
A Promising Step in Cancer Treatment
The recent toxicology studies were conducted on two species and confirmed that administering SIL204 does not result in any systemic organ toxicity. This result is crucial as it encourages Silexion to maintain timelines for launching a Phase 2/3 clinical trial aimed at treating locally advanced pancreatic cancer (LAPC).
Leadership Insights on SIL204's Progress
Ilan Hadar, Silexion's CEO, shared insights regarding the positive outcomes from the toxicology studies. “The results cleared our path to keep our scheduled timelines for the trial initiation of SIL204,” he stated. The company has reportedly partnered with a Contract Research Organization (CRO) to facilitate the trial process and is preparing submissions to health authorities in both Israel and Germany.
Strategic Approach to Treatment
Dr. Mitchell Shirvan, the Chief Scientific and Development Officer, elaborated on the company’s integrated treatment strategy. He expressed optimism regarding the favorable safety results supporting their treatment approach, which combines direct tumor injections with systemic administration. This dual method could be pivotal in addressing pancreatic cancer's high mortality rates.
About Silexion Therapeutics
Silexion Therapeutics is at the forefront of oncology, focusing on innovative therapies for cancers linked to the KRAS oncogene. The organization aims to push the boundaries of current treatments, particularly for stubborn cancers with few satisfactory options. The company previously conducted a Phase 2a clinical trial on its first-generation product, yielding promising results in comparison to traditional chemotherapy.
Next Steps in Clinical Development
With the positive toxicology study outcomes, the company is eager to advance SIL204’s development to the next clinical phase. By the second quarter of 2026, Silexion plans to initiate the first stage of advanced clinical trials. They remain committed to ensuring that this novel therapy reaches the patients who might benefit the most.
Company Contact:Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Contact:
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
With expectations high and the plan in action, Silexion Therapeutics stands prepared to revolutionize treatment options for those affected by pancreatic cancer.
Frequently Asked Questions
What is SIL204?
SIL204 is an innovative RNA silencing therapy developed by Silexion Therapeutics that targets mutated KRAS oncogenes associated with pancreatic cancer.
What were the findings of the toxicology studies?
The toxicology studies confirmed that SIL204 does not cause systemic organ toxicity, supporting its advancement to clinical trials.
When will the clinical trials for SIL204 begin?
Silexion Therapeutics plans to initiate the first stage of Phase 2/3 clinical trials in the second quarter of 2026.
Who leads Silexion Therapeutics?
Ilan Hadar serves as the Chairman and CEO of Silexion Therapeutics, guiding its strategic vision.
How does SIL204 compare to traditional cancer treatments?
SIL204 leverages an innovative RNA interference approach, aiming to inhibit cancer-driving proteins directly, which could provide new hope for patients with limited treatment options.
